- Low
- 52,000
- Average
- 114,309
- Median
- 113,880
- High
- 202,010
Biomarin Pharmaceutical Salary
23
74
66
Related Biomarin Pharmaceutical Salary
- CVS Salary
- Mayo Clinic Salary
- Cerner Salary
- Medtronic Salary
- Amgen Salary
- Qualcomm Technologies Salary
- Patni Americas Salary
- Ntt Data Salary
- Capgemini Financial Services Usa Salary
- Mastech, Inc., A Mastech Holdings, Inc. Salary
- Mindtree Salary
- Htc Global Services Salary
- L&t Technology Services Salary
- Kpit Infosystems Salary
Calculate how much you could earn
It's FREE. Based on your input and our analysis. How we do it?
All fields are required for calculation accuracy.
- We will send you an email to access your personalized report.
- We won’t share your email address
Real Jobs Salary - Salary List- 8.5 million company & government reported salaries with date & location
- Salary calculator rank & calculate your salary
- 151 million W-2s pay scale statistics in U.S.
- Salary Map helps you navigate location based salary information
- State & City Salary provides wage data by metropolitan areas
- Company Salaries has salaries data from over 200,000 companies
Biomarin Pharmaceutical Jobs
| See more Biomarin Pharmaceutical Jobs» | |
| Search All Jobs | |
Patents information
1719
All Patents
353
Grant Patents
1068
Patents Pending
356
Patents Families
More Recent
-
US11918633B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
-
US20240035013A1COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE VARIANTS AND METHODS OF USING COMPOSITIONS THEREOF
-
US20240058423A1Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same
- View More »
Biomarin Pharmaceutica... Information
- BioMarin Pharmaceutical
- Industry: BioTech/Drugs
- City: Novato, CA
- BioMarin Pharmaceutical Inc. develops enzyme therapies to treat debilitating, life-threatening genetic diseases and other indications. The Company has two enzyme replacement therapies in clinical trials and recently filed an application to enter a third enzyme into the clinic. Aldurazyme, a joint venture with Genzyme General, is an enzyme replacement therapy in a 45 patient, double-blind, placebo-controlled Phase III clinical trial to treat Mucopolysaccharidosis I (MPS I), a life-threatening genetic disease. On July 20, 2001, the Company completed the 24 week treatment stage of its Phase I clinical trial ofrhASB, an enzyme replacement therapy for the treatment of MPS VI,
